文献速递临床试验与 GCP基础与转化研究

慢性硬膜下血肿手术引流联合脑膜中动脉栓塞的随机临床试验

Management of Chronic Subdural Hematoma With Adjunctive Embolization of Middle Meningeal Artery: The EMMA-Can Randomized Clinical Trial.
PubMed 文献 · JAMA · 2026-01-01

EMMA-Can随机对照试验纳入192例单侧症状性慢性硬膜下血肿(≥10 mm)行手术引流的成人患者,比较术后72小时内追加脑膜中动脉栓塞(EMMA,Onyx-18)与单纯手术。90天CT证实的症状性复发率EMMA组4.3%对对照组28%(风险差-23.7,95%CI -34.1至-13.9,P<.001),影像学复发与严重不良事件两组接近。

要点

  • 术后72小时内追加EMMA显著降低90天症状性复发(4.3%对28%)。
  • 影像学复发EMMA组14%对对照组49.5%。
  • 严重不良事件8.6%对5.4%,死亡率4.3%对1.1%。

核心结论

  • 手术引流后追加EMMA可显著降低单侧慢性硬膜下血肿90天CT证实的症状性复发。

研究设计与样本

  • 随机、开放标签、盲法终点试验,在加拿大9家三级中心开展,2021年8月至2025年4月纳入成人单侧症状性慢性硬膜下血肿(≥10 mm)行手术引流者。
  • 192例随机分组,186例完成试验(每组93例;平均年龄71.8岁;男性136例,73%)。
  • 干预为术后72小时内使用液体栓塞剂Onyx-18行EMMA,对照组术后不接收EMMA。

主要发现

  • 90天CT证实的症状性复发:EMMA组4例(4.3%),对照组26例(28%),风险差-23.7(95%CI -34.1至-13.9,P<.001)。
  • 影像学复发:EMMA组13例(14%),对照组46例(49.5%)。
  • 死亡率:EMMA组4.3%,对照组1.1%;严重不良事件:EMMA组8.6%,对照组5.4%。

临床怎么用

  • 对符合试验条件的单侧症状性慢性硬膜下血肿(≥10 mm)手术引流患者,可考虑术后72小时内追加Onyx-18行EMMA以降低症状性复发。
  • 决策时需结合严重不良事件与死亡率数据个体化评估。

局限性

  • 开放标签设计,仅盲法评估终点。
  • 样本量186例完成试验,随访至90天(范围60至120天)。
  • 仅纳入加拿大9家三级中心人群,外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Chronic subdural hematomas commonly recur after surgical drainage. The effect of adjunctive embolization of the middle meningeal artery (EMMA) on recurrence risk remains unclear. OBJECTIVE: To evaluate whether EMMA as an adjunct to surgical drainage reduces chronic subdural hematoma recurrence compared with surgery alone. DESIGN, SETTING, AND PARTICIPANTS: This trial was a randomized, open-label, blinded-end point trial involving adults with unilateral, symptomatic chronic subdural hematoma (≥10 mm) undergoing surgical drainage across 9 tertiary care centers in Canada between August 2021 and April 2025. INTERVENTION: EMMA using a liquid embolic agent (Onyx-18) within 72 hours after surgical drainage vs a control group that did not receive EMMA after surgical drainage. MAIN OUTCOMES AND MEASURES: Primary outcome was symptomatic recurrence of chronic subdural hematoma detected on computed tomographic (CT) scan at 90 days (range, 60 to 120 days). Secondary outcomes included radiographic recurrence of chronic subdural hematoma, 90-day mortality, and serious adverse events. The last date of follow-up was July 27, 2025. RESULTS: Of 192 randomized participants, 186 (mean age, 71.8 years; 136 male [73%]) completed the trial (93 per group). The primary outcome of symptomatic recurrence of chronic subdural hematoma detected on CT scan occurred in 4 participants (4.3%) in the EMMA group vs 26 patients (28%) in the control group (risk difference, -23.7; 95% CI, -34.1 to -13.9; P < .001). Radiographic recurrence occurred in 13 participants (14%) in the EMMA group vs 46 patients (49.5%) in the control group. Mortality was 4.3% vs 1.1%; serious adverse events occurred in 8.6% vs 5.4%, respectively. CONCLUSIONS AND RELEVANCE: Adjunctive EMMA after surgical drainage significantly reduced symptomatic recurrence on CT scan of unilateral chronic subdural hematoma at 90 days compared with surgery alone. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04750200.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Shankar JJS, Alcock S, Kashani N, et al. Management of Chronic Subdural Hematoma With Adjunctive Embolization of Middle Meningeal Artery: The EMMA-Can Randomized Clinical Trial. JAMA. 2026. PMID: 42060283. doi:10.1001/jama.2026.4910

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。